Side-by-side · Research reference
PT-141vsThymosin α-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedReviewed13/41 cited
BPhase 3Reviewed8/39 cited
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
Thymosin α-1
Immune modulator · Approved (some countries)
SQ · 2× weekly · 6+ months for chronic indications
01Mechanism of Action
Parameter
PT-141
Thymosin α-1
Primary target
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001
Pathway
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007
Downstream effect
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007
Feedback intact?
—
—
Origin
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001
Antibody development
—
—
02Dosage Protocols
Parameter
PT-141
Thymosin α-1
Standard dose
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
—
Frequency
PRN, max 8 doses / month
2× weekly (Mon/Thu typical)
Lower / starter dose
1 mg (off-label)
0.8 mg per injection
Evidence basis
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007
Duration
PRN; reassess if no benefit after 8 doses
6–12 months for chronic indications
Reconstitution
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Sterile water for injection per vial label
Timing
≥45 min before sexual activity
No specific time
04Side Effects & Safety
Parameter
PT-141
Thymosin α-1
Flushing
Common, transient
—
Injection site reaction
Erythema, mild pain
Erythema, mild discomfort
Headache
Common
—
Hyperpigmentation (focal)
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
—
Hypertension (transient)
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
—
Pregnancy / OB
Contraindicated
Avoid
Cardiovascular disease
Use caution; transient BP rise
—
GI symptoms
—
Rare nausea
Fatigue
—
Common during initial weeks
Fever / flu-like
—
Mild interferon-like response possible
Autoimmune
—
Theoretical risk; caution in active autoimmune disease
Cancer risk
—
No signal — used as adjuvant in oncology
Absolute Contraindications
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Thymosin α-1
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
- ·Concurrent immunosuppressant therapy (transplant patients)
Relative Contraindications
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
Thymosin α-1
- ·Active autoimmune disease
- ·Severe immunocompromised state without supervision
05Administration Protocol
Parameter
PT-141
Thymosin α-1
1. Reconstitution
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.
2. Injection site
SQ — abdomen or thigh.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Timing
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
2× weekly, e.g. Monday + Thursday.
4. Storage
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.
5. Needle
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
27–31G, 4–8 mm insulin syringe.